Palisade Bio, Inc. Share Price & Technical Analysis
PALI · $1.95 (-2.99%)
Healthcare / Biotechnology
$1.95
-2.99%
Palisade Bio, Inc., a clinical-stage biopharmaceutical company, engages in developing oral phosphodiesterase-4 inhibitor prodrugs designed for targeted delivery to the terminal ileum and colon in the United States. Its lead clinical product candidate includes PALI-2108, which is in phase 1b clinical trial to treat patients with inflammatory bowel disease, including ulcerative colitis and Fibrosten…
Price chart
Seasonality
May has 0 positive and 4 negative years (last 5 years shown)
0% return in May, -23% avg return in past 3 year May month.
3% return in 2026, -40% avg return in past 3 years.
Swipe sideways to see all months →
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Yr | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 26 | -35% | 20% | 0% | 18% | 0% | – | – | – | – | – | – | – | 3% |
| 25 | -26% | -38% | -12% | 33% | -12% | 0% | 43% | -30% | 29% | 110% | 5% | 10% | 109% |
| 24 | 3% | -34% | -5% | -3% | -39% | -6% | -17% | -10% | 0% | -23% | -4% | -36% | -174% |
| 23 | -38% | -24% | 60% | -34% | -17% | 31% | 37% | -70% | -15% | 2% | 15% | -2% | -55% |
| 22 | -10% | -21% | 14% | -26% | -32% | -24% | -5% | -59% | -33% | -10% | -14% | 34% | -187% |
Monthly return % by calendar month · historical pattern, not a forecast
Neutral · Emerging · Neutral
Palisade Bio, Inc., a clinical-stage biopharmaceutical company, engages in developing oral phosphodiesterase-4 inhibitor prodrugs designed for targeted delivery to the terminal ileum and colon in the United States. Its lead clinical product candidate includes PALI-2108, which is in phase 1b clinical trial to treat patients with inflammatory bowel disease, including ulcerative colitis and Fibrostenotic Crohn's disease. The company has a research collaboration and license agreement with Giiant Pharma, Inc. for the development, manufacture, and commercialization of its compounds; license agreement with the Regents of the University of California for sole purpose of maintaining the Newsoara Co-Development; and a co-development and distribution agreement with Newsoara Biopharma Co., Ltd. The company was founded in 2001 and is headquartered in Denver, Colorado.
Full AI Q&A, portfolio tracking, and live alerts in the app.
Key metrics
Market cap
$320.16M
P/E ratio
—
52W high
$2.86
52W low
$0.53
Volume
32,60,567
Beta
1.53
Related stocks in Healthcare
Merck & Co Inc Cedear (5…
₹32,900
Abbott Laboratories Cede…
₹30,500
Eli Lilly And Company Ce…
₹25,540
Unitedhealth Group Inc C…
₹17,200
₹6,600
Frequently asked questions
- What is Palisade Bio, Inc. share price today?
- Palisade Bio, Inc. (PALI) last traded around $1.95 on StockPro. Prices refresh every few minutes during market hours.
- What technical signals does PALI have?
- StockPro monitors breakouts, volume spikes, EMA reversals, and momentum for PALI. Download the app for real-time alerts.
- How can I analyze Palisade Bio, Inc. stock?
- Use the price chart, seasonality heatmap, key metrics, and AI insight on this page. For portfolio tracking and push alerts, download StockPro on Android or iOS.